Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2001 Aug 1;357(Pt 3):709–718. doi: 10.1042/0264-6021:3570709

A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.

M C Walker 1, R G Kurumbail 1, J R Kiefer 1, K T Moreland 1, C M Koboldt 1, P C Isakson 1, K Seibert 1, J K Gierse 1
PMCID: PMC1222000  PMID: 11463341

Abstract

Cyclo-oxygenase (COX) enzymes are the targets for non-steroidal anti-inflammatory drugs (NSAIDs). These drugs demonstrate a variety of inhibitory mechanisms, which include simple competitive, as well as slow binding and irreversible inhibition. In general, most NSAIDs inhibit COX-1 and -2 by similar mechanisms. A unique class of diarylheterocyclic inhibitors has been developed that is highly selective for COX-2 by virtue of distinct inhibitory mechanisms for each isoenzyme. Several of these inhibitors, with varying selectivity, have been utilized to probe the mechanisms of COX inhibition. Results from analysis of both steady-state and time-dependent inhibition were compared. A generalized mechanism for inhibition, consisting of three sequential reversible steps, can account for the various types of kinetic behaviour observed with these inhibitors.

Full Text

The Full Text of this article is available as a PDF (191.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett A. Overview of nimesulide. Rheumatology (Oxford) 1999 May;38 (Suppl 1):1–3. doi: 10.1093/rheumatology/38.suppl_1.1. [DOI] [PubMed] [Google Scholar]
  2. Bhattacharyya D. K., Lecomte M., Rieke C. J., Garavito M., Smith W. L. Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1. J Biol Chem. 1996 Jan 26;271(4):2179–2184. doi: 10.1074/jbc.271.4.2179. [DOI] [PubMed] [Google Scholar]
  3. Callan O. H., So O. Y., Swinney D. C. The kinetic factors that determine the affinity and selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by indomethacin and flurbiprofen. J Biol Chem. 1996 Feb 16;271(7):3548–3554. doi: 10.1074/jbc.271.7.3548. [DOI] [PubMed] [Google Scholar]
  4. Chan C. C., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D., Evans J., Ford-Hutchinson A. W., Forrest M. J., Gauthier J. Y. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999 Aug;290(2):551–560. [PubMed] [Google Scholar]
  5. Chen W., Pawelek T. R., Kulmacz R. J. Hydroperoxide dependence and cooperative cyclooxygenase kinetics in prostaglandin H synthase-1 and -2. J Biol Chem. 1999 Jul 16;274(29):20301–20306. doi: 10.1074/jbc.274.29.20301. [DOI] [PubMed] [Google Scholar]
  6. Copeland R. A., Williams J. M., Giannaras J., Nurnberg S., Covington M., Pinto D., Pick S., Trzaskos J. M. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11202–11206. doi: 10.1073/pnas.91.23.11202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cryer B., Dubois A. The advent of highly selective inhibitors of cyclooxygenase--a review. Prostaglandins Other Lipid Mediat. 1998 Aug;56(5-6):341–361. doi: 10.1016/s0090-6980(98)00064-1. [DOI] [PubMed] [Google Scholar]
  8. Dubois R. N., Abramson S. B., Crofford L., Gupta R. A., Simon L. S., Van De Putte L. B., Lipsky P. E. Cyclooxygenase in biology and disease. FASEB J. 1998 Sep;12(12):1063–1073. [PubMed] [Google Scholar]
  9. Futaki N., Takahashi S., Yokoyama M., Arai I., Higuchi S., Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 1994 Jan;47(1):55–59. doi: 10.1016/0090-6980(94)90074-4. [DOI] [PubMed] [Google Scholar]
  10. Gans K. R., Galbraith W., Roman R. J., Haber S. B., Kerr J. S., Schmidt W. K., Smith C., Hewes W. E., Ackerman N. R. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther. 1990 Jul;254(1):180–187. [PubMed] [Google Scholar]
  11. Gierse J. K., Hauser S. D., Creely D. P., Koboldt C., Rangwala S. H., Isakson P. C., Seibert K. Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J. 1995 Jan 15;305(Pt 2):479–484. doi: 10.1042/bj3050479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gierse J. K., Koboldt C. M., Walker M. C., Seibert K., Isakson P. C. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J. 1999 May 1;339(Pt 3):607–614. [PMC free article] [PubMed] [Google Scholar]
  13. Gierse J. K., McDonald J. J., Hauser S. D., Rangwala S. H., Koboldt C. M., Seibert K. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem. 1996 Jun 28;271(26):15810–15814. doi: 10.1074/jbc.271.26.15810. [DOI] [PubMed] [Google Scholar]
  14. Guo Q., Wang L. H., Ruan K. H., Kulmacz R. J. Role of Val509 in time-dependent inhibition of human prostaglandin H synthase-2 cyclooxygenase activity by isoform-selective agents. J Biol Chem. 1996 Aug 9;271(32):19134–19139. doi: 10.1074/jbc.271.32.19134. [DOI] [PubMed] [Google Scholar]
  15. Huang Z. F., Wun T. C., Broze G. J., Jr Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem. 1993 Dec 25;268(36):26950–26955. [PubMed] [Google Scholar]
  16. KITZ R., WILSON I. B. Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem. 1962 Oct;237:3245–3249. [PubMed] [Google Scholar]
  17. Kalgutkar A. S., Crews B. C., Rowlinson S. W., Garner C., Seibert K., Marnett L. J. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. Science. 1998 May 22;280(5367):1268–1270. doi: 10.1126/science.280.5367.1268. [DOI] [PubMed] [Google Scholar]
  18. Kurumbail R. G., Stevens A. M., Gierse J. K., McDonald J. J., Stegeman R. A., Pak J. Y., Gildehaus D., Miyashiro J. M., Penning T. D., Seibert K. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996 Dec 19;384(6610):644–648. doi: 10.1038/384644a0. [DOI] [PubMed] [Google Scholar]
  19. Lanzo C. A., Sutin J., Rowlinson S., Talley J., Marnett L. J. Fluorescence quenching analysis of the association and dissociation of a diarylheterocycle to cyclooxygenase-1 and cyclooxygenase-2: dynamic basis of cyclooxygenase-2 selectivity. Biochemistry. 2000 May 23;39(20):6228–6234. doi: 10.1021/bi992761o. [DOI] [PubMed] [Google Scholar]
  20. Lecomte M., Laneuville O., Ji C., DeWitt D. L., Smith W. L. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem. 1994 May 6;269(18):13207–13215. [PubMed] [Google Scholar]
  21. Loll P. J., Picot D., Ekabo O., Garavito R. M. Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Biochemistry. 1996 Jun 11;35(23):7330–7340. doi: 10.1021/bi952776w. [DOI] [PubMed] [Google Scholar]
  22. Marnett L. J., Rowlinson S. W., Goodwin D. C., Kalgutkar A. S., Lanzo C. A. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J Biol Chem. 1999 Aug 13;274(33):22903–22906. doi: 10.1074/jbc.274.33.22903. [DOI] [PubMed] [Google Scholar]
  23. Morrison J. F., Walsh C. T. The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol. 1988;61:201–301. doi: 10.1002/9780470123072.ch5. [DOI] [PubMed] [Google Scholar]
  24. Ouellet M., Percival M. D. Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306(Pt 1):247–251. doi: 10.1042/bj3060247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Penning T. D., Talley J. J., Bertenshaw S. R., Carter J. S., Collins P. W., Docter S., Graneto M. J., Lee L. F., Malecha J. W., Miyashiro J. M. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem. 1997 Apr 25;40(9):1347–1365. doi: 10.1021/jm960803q. [DOI] [PubMed] [Google Scholar]
  26. Picot D., Loll P. J., Garavito R. M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature. 1994 Jan 20;367(6460):243–249. doi: 10.1038/367243a0. [DOI] [PubMed] [Google Scholar]
  27. Riendeau D., Percival M. D., Boyce S., Brideau C., Charleson S., Cromlish W., Ethier D., Evans J., Falgueyret J. P., Ford-Hutchinson A. W. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121(1):105–117. doi: 10.1038/sj.bjp.0701076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Rome L. H., Lands W. E. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci U S A. 1975 Dec;72(12):4863–4865. doi: 10.1073/pnas.72.12.4863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Roth G. J., Stanford N., Majerus P. W. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975 Aug;72(8):3073–3076. doi: 10.1073/pnas.72.8.3073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Seibert K., Masferrer J. L. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor. 1994 Spring;4(1):17–23. [PubMed] [Google Scholar]
  31. Shah A. A., Murray F. E., Fitzgerald D. J. The in vivo assessment of nimesulide cyclooxygenase-2 selectivity. Rheumatology (Oxford) 1999 May;38 (Suppl 1):19–23. doi: 10.1093/rheumatology/38.suppl_1.19. [DOI] [PubMed] [Google Scholar]
  32. Smith C. J., Zhang Y., Koboldt C. M., Muhammad J., Zweifel B. S., Shaffer A., Talley J. J., Masferrer J. L., Seibert K., Isakson P. C. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13313–13318. doi: 10.1073/pnas.95.22.13313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Smith W. L., Garavito R. M., DeWitt D. L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem. 1996 Dec 27;271(52):33157–33160. doi: 10.1074/jbc.271.52.33157. [DOI] [PubMed] [Google Scholar]
  34. Smith W. L., Marnett L. J. Prostaglandin endoperoxide synthase: structure and catalysis. Biochim Biophys Acta. 1991 Apr 24;1083(1):1–17. doi: 10.1016/0005-2760(91)90119-3. [DOI] [PubMed] [Google Scholar]
  35. So O. Y., Scarafia L. E., Mak A. Y., Callan O. H., Swinney D. C. The dynamics of prostaglandin H synthases. Studies with prostaglandin h synthase 2 Y355F unmask mechanisms of time-dependent inhibition and allosteric activation. J Biol Chem. 1998 Mar 6;273(10):5801–5807. doi: 10.1074/jbc.273.10.5801. [DOI] [PubMed] [Google Scholar]
  36. Swinney D. C., Mak A. Y., Barnett J., Ramesha C. S. Differential allosteric regulation of prostaglandin H synthase 1 and 2 by arachidonic acid. J Biol Chem. 1997 May 9;272(19):12393–12398. doi: 10.1074/jbc.272.19.12393. [DOI] [PubMed] [Google Scholar]
  37. Van Der Ouderaa F. J., Buytenhek M., Nugteren D. H., Van Dorp D. A. Acetylation of prostaglandin endoperoxide synthetase with acetylsalicylic acid. Eur J Biochem. 1980 Aug;109(1):1–8. doi: 10.1111/j.1432-1033.1980.tb04760.x. [DOI] [PubMed] [Google Scholar]
  38. Vane J. R., Bakhle Y. S., Botting R. M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97–120. doi: 10.1146/annurev.pharmtox.38.1.97. [DOI] [PubMed] [Google Scholar]
  39. Warner T. D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J. A., Vane J. R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7563–7568. doi: 10.1073/pnas.96.13.7563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Wong E., Bayly C., Waterman H. L., Riendeau D., Mancini J. A. Conversion of prostaglandin G/H synthase-1 into an enzyme sensitive to PGHS-2-selective inhibitors by a double His513 --> Arg and Ile523 --> val mutation. J Biol Chem. 1997 Apr 4;272(14):9280–9286. doi: 10.1074/jbc.272.14.9280. [DOI] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES